Panacea Biotec

*Innovation in support of life*

**Panacea Biotec presents**

**PREVENT –Diabetes & Complications in India: Perspectives & Treatment Options**

New Delhi, 16th April, 2011: Panacea Biotec, India's 3rd largest biotechnology company proudly presents book PREVENT –Diabetes & Complications in India: Perspective & Treatment Options.

PREVENT, 1st time in India, is a book which attempts to address management guidelines of diabetes and complications based on Indian perspective.

India today is at the ascending limb of the epidemic diabetes with the prevalence and incidence increasing at an alarming rate. It is a matter of concern that lack of awareness, late diagnosis and inadequate management is resulting in compounding the patients' misery. Moreover, there is no concrete guidance to manage Indian diabetics as we are genetically conducive to develop diabetes and complications. Taking a note from what is the need of the hour, an eminent panel from across India, comprising of renowned Diabetologists , Cardiologists, Nephrologist, Neurologist and Retionologist, under the chairmanship of Padmashree Dr. Anoop Misra has endeavored to put in evidence and practical experience and come up with the book PREVENT. The honorable endocrinologist & diabetologist involved in this are Dr. Subhankar Choudhury (Kolkata), Dr. Vijay Viswanathan (Chennai), Dr. H B Chandalia (Mumbai) & Dr. Bansi Saboo (Ahmedabad); honorable cardiologists are Dr. R R Kasliwal (Guragaon & Delhi NCR), Dr. G S Wander (Ludhiana) & Dr. Anjan Lal Dutta (Kolkata); neurologist Dr. P P Ashok (Mumbai); nephrologist Dr. Bharat Shah (Mumbai) and retina specialist Dr. N S Muralidhar (Bangalore). Therefore, PREVENT is a blend of experience from across India.

Commenting on the same, **Dr. Anoop Misra, Chairman PREVENT**, said *"For the 1st time this comprehensively written book will be available to clinicians dealing with diabetes patients with complications. PREVENT will help them to use evidence based strategies for effective diagnosis, prevention and management of complications of diabetes .In particular all these guidelines are adapted to locally specific situations and practices as is seen in Indian subcontinent"*. He has thanked Panacea Biotec for the valuable support in ideation and executing this project successfully. He has also expressed his thanks to Elsevier for the cooperation in creating the scientific content of PREVENT.

Panacea Biotec Ltd.

**Dr. Rajesh Jain, Jt. Managing Director, Panacea Biotec Limited.** Expressed his views "Diabetes is the single most important metabolic disease which can affect nearly every organ system in the body. People with diabetes are 25 times more likely to develop blindness, 17 times more likely to develop kidney disease, 30-40 times more likely to undergo amputations, 2-4 times more likely to develop MI and twice as likely to suffer a stroke than non diabetics. This will pose a threat to our economic progress and development".

"The book – Prevent – diabetes & complication is a very good attempt to educate people about the disease, its management and prevention. The vast world population is looking ahead to live a happy, healthy and longer life and this book will provide guidance and expert solutions".

"Panacea Biotec has always contributed in providing solutions for health management and will remain committed to the cause of helping Indian clinicians to manage diabetes and its complications".

## Notes to the Editors

**About Panacea Biotec**

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey- 2010) and is also amongst the top 50 pharmaceutical companies in India. The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. Panacea Biotec has five dedicated research and development centers. The company has around 3300 employees including over 300 scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.

For Further details please contact:

Subhash Y Mantri
GM- Corporate Communication
Mobile: +91-9871430022
Land Line: +91-11-4167 9000; Fax: +91-11-26940621
Email: subhashmantri@panaceabiotec.com
Website: www.panaceabiotec.com